Bibliographic record

Efficacy and safety of once-weekly semaglutide monotherapy versus placebo in patients with type 2 diabetes…

Sorli C, Harashima SI, Tsoukas GM, Unger J, Karsbøl JD, Hansen T, Bain SC. The Lancet Diabetes & Endocrinology 2017

Document identifier: CEI-BR-103
Series: Bibliographic record
Version: 1.0
Published: 30 Jul 2026
Last reviewed: 30 Jul 2026
Certainty: Not rated

§1Bibliographic record

§1.1Record

Authors: Sorli C, Harashima SI, Tsoukas GM, Unger J, Karsbøl JD, Hansen T, Bain SC
Title: Efficacy and safety of once-weekly semaglutide monotherapy versus placebo in patients with type 2 diabetes (SUSTAIN 1): a double-blind, randomised, placebo-controlled, parallel-group, multinational, multicentre phase 3a trial
Source: The Lancet Diabetes & Endocrinology
Year: 2017
Volume, issue, pages: 5(4):251–260
Digital object identifier: 10.1016/S2213-8587(17)30013-X
PubMed identifier: 28110911
Record type: Journal article
Institute identifier: CEI-BR-103

§1.2Institute documents citing this record

No Institute document currently cites this record. It is held in the bibliography because it was retrieved during a search and assessed, and the Institute records what it assessed and did not use as well as what it used.

§1.3Subject tags

semaglutide t2dm SUSTAIN

Compound Evidence Institute · CEI-BR-103 · https://compoundevidence.com/bibliography/sorli2017/ · retrieved 30 July 2026